A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Administration With Prefilled Pen Relative to a Prefilled Syringe in Healthy Adult Participants

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 8, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

Healthy Volunteers

Interventions

DRUG

Risankizumab

Subcutaneous Injection

Trial Locations (2)

Acpru /Id# 275116, Grayslake

Altasciences Clinical Los Angeles /ID# 276446, Cypress